ID   PK-8
AC   CVCL_4718
SY   PK8
DR   BTO; BTO:0004855
DR   CLO; CLO_0050112
DR   EFO; EFO_0006737
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472951
DR   Cosmic; 707254
DR   Cosmic; 1066177
DR   Cosmic; 1644298
DR   IARC_TP53; 14302
DR   PharmacoDB; PK8_1269_2019
DR   RCB; RCB2096
DR   RCB; RCB2700
DR   TKG; TKG 0383
DR   Wikidata; Q54947454
RX   PubMed=3547771;
RX   PubMed=11115575;
RX   PubMed=25485619;
RX   PubMed=26216984;
CC   Characteristics: Established from a xenograft.
CC   Doubling time: 56 hours (PubMed=3547771).
CC   Sequence variation: Hemizygous for KRAS p.Gly12Arg (c.34G>C) (PubMed=11115575).
CC   Sequence variation: TP53 p.Gln167Ter (c.499C>T) (PubMed=11115575).
CC   Omics: Deep RNAseq analysis.
CC   Omics: Metabolome analysis.
CC   Omics: SNP array analysis.
CC   Discontinued: RCB; RCB2096; true.
CC   Derived from metastatic site: Liver.
ST   Source(s): PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 9,10
ST   D18S51: 13
ST   D21S11: 31
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 9,12
ST   D8S1179: 13,15
ST   FGA: 23
ST   Penta D: 9
ST   Penta E: 13,15
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 16
//
RX   PubMed=3547771; DOI=10.1620/tjem.150.231;
RA   Kobari M., Hisano H., Matsuno S., Sato T., Kan M., Tachibana T.;
RT   "Establishment of six human pancreatic cancer cell lines and their
RT   sensitivities to anti-tumor drugs.";
RL   Tohoku J. Exp. Med. 150:231-248(1986).
//
RX   PubMed=11115575; DOI=10.3892/or.8.1.89;
RA   Sun C., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.;
RT   "Characterization of the mutations of the K-ras, p53, p16, and SMAD4
RT   genes in 15 human pancreatic cancer cell lines.";
RL   Oncol. Rep. 8:89-92(2001).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//